SML2117

TCS-1102

≥98% (HPLC)

• Synonym(e): BBAC, (2S)-N-[1,1′-Biphenyl]-2-yl-1-[2-[(1-methyl-1H-benzimidazol-2-yl)thio]acetyl]-2-pyrrolidinecarboxamide, DORA-1, N-(1,1′-Biphenyl-2-yl)-1-{[(1-methyl-1H-benzimidazol-2-yl)thio]acetyl}-L-prolinamide, TCS 1102, TCS1102, (2S)-N-[1,1′-Biphenyl]-2-yl-1-[2-[(1-methyl-1H-benzimidazol-2-yl)thio]acetyl]-2-pyrrolidinecarboxamide
• Empirische Formel (Hill-System): C₂₇H₂₆N₄O₂S
• CAS-Nummer: 916141-36-1
• Molekulargewicht: 470.59
• MDL-Nummer: MFCD18086894
• UNSPSC-Code: 12352200

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: CN1C2=CC=CC=C2N=C1SCC(N3CCC[C@H]3C(NC4=CC=CC=C4C5=CC=CC=C5)=O)=O
• InChI: 1S/C27H26N4O2S/c1-30-23-15-8-7-14-22(23)29-27(30)34-18-25(32)31-17-9-16-24(31)26(33)28-21-13-6-5-12-20(21)19-10-3-2-4-11-19/h2-8,10-15,24H,9,16-18H2,1H3,(H,28,33)/t24-/m0/s1
• InChIKey: YSBGRVXJEMSEQY-DEOSSOPVSA-N

Beschreibung

Biochem./physiol. Wirkung

TCS-1102 (DORA-1) is a high-affinity (Ki = 3 nM against [3H]-TCS-1102 for binding hOX₁R and Ki = 0.2 nM against [3H]-pyrrolylphenyl analog for binding hOX₂R) dual orexin receptor antagonist (DORA) that potently inhibits calcium mobilization in hOX₁R & hOX₂R CHO transfectants (IC50 = 17 & 4 nM, respectively). TCS-1102 promotes sleep (50-100 mg/kg p.o.), decreases fear/anxiety (10-20 mg/kg i.p.), and inhibits ADL-orexin B peptide-induced locomotion (by 56%/74%/100% with 15/50/100 mg/kg i.p. 30 min before ADL-XB ICV injection) with good pharmacokinetic properties, brain penetration (Brain/plasma conc. = 2.37 μM/3.50 μM 3 hrs post 100 mg/kg i.p.), and oral availability (Cmax/AUC(0–24h) = 1.21 μM/6.8 μM h and 3.01 μM/12.5 μM h, respectively post 50 and 100 mg/kg p.o. dosage) in rats in vivo.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable